Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of PF-06939926 in Duchenne muscular dystrophy
KCT0005683Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Feb 2021
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing PF-06939926 with Placebo (2 arms). Started Feb 2021; status: recruiting.
02
Drugs
fordadistrogene movaparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on KCT0005683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005683.